证券代码：837344 证券简称：三元基因 公告编号：2024-052 北京三元基因药业股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 5 月 14 日 2.会议召开地点：公司会议室 3.会议召开方式：现场投票和网络投票相结合的方式 4.会议召集人：公司董事会 5.会议主持人：董事长程永庆 6.召开情况合法、合规、合章程性说明： 会议的召集、召开、议案审议程序符合《公司法》等有关法律、 法规和《公司章程》的规定。 （二）会议出席情况 出席和授权出席本次股东大会的股东共 18 人，持有表决权的股 份总数 87,814,374 股，占公司有表决权股份总数的 72.0913%。 其中通过网络投票参与本次股东大会的股东共 7 人，持有表决权 的股份总数 12,624,323 股，占公司有表决权股份总数的 10.3639%。 （三）公司董事、监事、高级管理人员出席或列席股东大会情况 1.公司 ...

北京三元基因药业股份有限公司章程 公告编号：2024-054 北京三元基因药业股份有限公司 公司章程 二○二四年四月 1 / 67 | 第一章 | 总则 | 4 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 5 | | 第三章 | 股份 | 5 | | 第一节 | 股份发行 | 5 | | 第二节 | 股份增减和回购 | 6 | | 第三节 | 股份转让 | 7 | | 第四章 | 股东和股东大会 | 8 | | 第一节 | 股东 | 8 | | 第二节 | 股东大会的一般规定 | 12 | | 第三节 | 股东大会的召集 | 16 | | 第四节 | 股东大会的提案与通知 | 17 | | 第五节 | 股东大会的召开 | 19 | | 第六节 | 股东大会的表决和决议 | 22 | | 第五章 | 董事会 | 31 | | 第一节 | 董事 | 31 | | 第二节 | 董事会 | 39 | | 第三节 | 董事会秘书 | 45 | | 第六章 | 总经理及其他高级管理人员 | 47 | | 第七章 | 监事会 | 49 | | 第一节 | 监事 | 49 | | 第二节 ...

证券代码：837344 证券简称：三元基因 公告编号：2024-051 北京三元基因药业股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 投资者关系活动类别 □特定对象调研 √业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 ...

证券代码：837344 证券简称：三元基因 公告编号：2024-050 北京三元基因药业股份有限公司 2023 年年度报告业绩说明会预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 说明会类型 北京三元基因药业股份有限公司（以下简称"公司"）于 2024 年 4 月 15 日在北京证券交易所官网（www.bse.cn）披露了《北京三元 基因药业股份有限公司 2023 年年度报告》（公告编号：2024-007）， 为方便广大投资者更深入了解公司 2023 年年度经营业绩的具体情 况，公司拟召开 2023 年年度报告业绩说明会。 申万宏源证券承销保荐有限责任公司保荐代表人： 徐鸿宇先生、潘志源先生 （二）会议召开地点 本次年度报告业绩说明会将采用网络远程的方式举行，投资者可 登陆中证路演中心（https://www.cs.com.cn/roadshow/）参与本次年 度业绩说明会。 三、 参加人员 公司董事长、总经理：程永庆先生 公司副总经理：刘金毅先生 公司财务负责人、副总经理：张凤琴女士 ...

证券代码：837344 证券简称：三元基因 公告编号：2024-048 北京三元基因药业股份有限公司 第三届董事会第十七次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、会议召开和出席情况 （一）会议召开情况 1.会议召开时间：2024 年 4 月 24 日 4.发出董事会会议通知的时间和方式：2024 年 4 月 13 日以通讯 方式发出。 5.会议主持人：会议由程永庆董事长主持。 6.会议列席人员：监事会成员、董事会秘书以及公司其他高级管 理人员列席了会议。 7.召开情况合法、合规、合章程性说明： 会议的召开符合《公司法》和《公司章程》等有关规定。 2.会议召开地点：公司会议室 3.会议召开方式：现场+通讯方式 （二）会议出席情况 会议应出席董事 7 人，出席和授权出席董事 7 人。 董事程十庆因公务出差以通讯方式参与表决。 董事杨大军因公务出差以通讯方式参与表决。 2.议案表决结果：同意 7 票；反对 0 票；弃权 0 票。 上述议案已经董事会审计委员会会议审议通过。 3.回避表 ...

Financial Performance - Operating revenue for Q1 2024 reached CNY 47,952,373.12, representing a 39.49% increase year-over-year [10]. - Net profit attributable to shareholders for Q1 2024 was CNY 1,928,398.18, up 9.87% from the same period last year [10]. - The company's gross profit margin increased, with operating costs rising by 41.20% to CNY 9,185,324.05 due to higher sales volume [12]. - The company’s basic earnings per share doubled to CNY 0.02 from CNY 0.01 in the previous year [10]. - Total revenue for Q1 2024 reached ¥47,952,373.12, a significant increase of 39.6% compared to ¥34,376,162.80 in Q1 2023 [43]. - Operating profit for Q1 2024 was ¥2,240,369.16, slightly up from ¥2,202,164.55 in Q1 2023, indicating a stable performance [44]. - Net profit for Q1 2024 was ¥1,928,398.18, representing a 9.8% increase from ¥1,755,211.84 in Q1 2023 [44]. - Earnings per share for Q1 2024 were ¥0.02, consistent with Q1 2023 [45]. Cash Flow and Assets - The net cash flow from operating activities was CNY 15,256,581.97, a significant increase of 233.62% compared to Q1 2023 [10]. - Operating cash inflow for Q1 2024 was CNY 66,423,147.36, a significant increase from CNY 36,843,520.22 in Q1 2023, representing an increase of 80.2% [48]. - Cash outflow for investment activities decreased to CNY 46,173,069.57 in Q1 2024 from CNY 108,461,515.10 in Q1 2023, indicating a reduction of 57.4% [49]. - Cash inflow from financing activities was CNY 32,523,874.00 in Q1 2024, down from CNY 77,700,006.08 in Q1 2023, a decrease of 58.2% [49]. - The ending cash and cash equivalents balance for Q1 2024 was CNY 157,128,684.11, down from CNY 180,526,369.49 in Q1 2023 [49]. - Total current assets decreased to CNY 276,537,250.04 from CNY 306,918,274.64, a decline of approximately 9.9% [37]. - Cash and cash equivalents decreased to CNY 157,128,684.11 from CNY 177,507,670.01, a decrease of about 11.5% [37]. - Accounts receivable decreased to CNY 70,872,074.34 from CNY 83,602,734.13, representing a decline of approximately 15.3% [37]. - Total non-current assets increased to CNY 944,751,490.26 from CNY 928,255,592.19, an increase of about 1.5% [38]. - Total assets as of March 31, 2024, were CNY 1,221,288,740.30, a decrease of 1.12% compared to the end of 2023 [10]. Liabilities and Equity - The asset-liability ratio for the consolidated entity decreased to 49.75% from 50.54% year-over-year [10]. - Total liabilities decreased to CNY 607,605,085.13 from CNY 624,235,299.84, a reduction of approximately 2.6% [39]. - Total equity increased to CNY 613,683,655.17 from CNY 610,938,566.99, an increase of about 0.4% [39]. - Long-term borrowings increased to CNY 438,250,530.75 from CNY 414,229,240.81, an increase of approximately 5.8% [39]. - The largest shareholder, Beijing Southeast Pharmaceutical Investment Holding Co., Ltd., holds 46,907,925 shares, accounting for 38.51% of the total shares [19]. Research and Development - The company has completed the Phase III clinical trial for interferon α1b nebulization treatment for RSV pneumonia in children, showing significant efficacy and safety, with a reduction in clinical symptom duration by nearly one day within 72 hours of treatment [28]. - The company has initiated a Phase III clinical trial for interferon α1b in the prevention and treatment of COVID-19, with 400 patients enrolled across three newly approved clinical centers [29]. - The predictive accuracy for E antigen seroconversion and S antigen negativity in the new PEG-integrated interferon clinical trial has reached 84% and 75%, respectively [30]. - The company has improved the expansion process of γδT cells from 450 times to 16,000 times, significantly increasing the yield of cell preparations for tumor immunotherapy [31]. - Research and development expenses for Q1 2024 were ¥2,924,856.44, up from ¥2,518,540.70 in Q1 2023, highlighting a focus on innovation [43]. Operational Developments - The new intelligent production and R&D base has been recognized as a key project by the Beijing government, with an annual production capacity exceeding 100 million units across various dosage forms [32]. - The new facility incorporates advanced technologies such as industrial internet and big data analysis, aiming to enhance operational efficiency and reduce costs [33]. - The construction of the new facility has entered the completion and acceptance phase, with various approvals obtained from local authorities [34]. Commitments and Legal Matters - There are no significant changes in the disclosed commitments, and all commitments have been strictly adhered to [24]. - There are no litigation or arbitration matters reported during the reporting period [22]. - The company has not experienced any significant changes in shareholder equity or major transactions during the reporting period [22].

| 1-5 | | --- | | 6-7 | | 8 | | 9 | | 10-11 | | 12-13 | | 14 | | 15 | | 16-17 | | 18-91 | CAC [2024]0033 CAC [2024]0033 2023 12 31 2023 2023 12 31 2023 1 2023 1 1 24,473.30 2 1 5 6 7 1. 2023 11,316.96 2023 8,443.54 2. 2 3 4 1 2 2 3 4 5 6 7 2023 3 治理层负责监督北京三元基因公司的财务报告过程。 六、注册会计师对财务报表审计的责任 我们的目标是对财务报表整体是否不存在由于舞弊或错误导致的重大错报获取 合理保证,并出具包含审计意见的审计报告。合理保证是高水平的保证,但并不能 保证按照审计准则执行的审计在某一重大错报存在时总能发现。错报可能由于舞弊 或错误导致,如果合理预期错报单独或汇总起来可能影响财务报表使用者依据财务 报表作出的经济决策,则通常认为错报是重大的。 在按照审计准则执行审计工作的过程中,我们运用职业判断,并保持职业怀疑。 同时,我们也执行以下工作: (1) ...

北京三元基因药业股份有限公司 2023 年度募集资金存放与实际使用情况 鉴证报告 CAC 证专字[2024]0048 号 中审华会计师事务所（特殊普通合伙） 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn） "进行查 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://ac.mof.gov.cn） "进行查... " | 달 录 | | | --- | --- | | 目录 | 页次 | | 一、募集资金年度存放与实际使用情况鉴证报告 | 1-2 | | 二、北京三元基因药业股份有限公司 2022年度募集资金存放与 | 3-7 | 实际使用情况的专项报告 募集资金年度存放与实际使用情况鉴证报告 CAC 证专字[2024]0048 号 北京三元基因药业股份有限公司全体股东: 我们接受委托,对后附的北京三元基因药业股份有限公司(以下简称贵公司) 《2023 年度募集资金存放与实际使用情况的专项报告》进行了鉴证。 一、对报告使用者和使用目的的限定 本鉴证报告仅供贵公司年度报告披露时使用,不得用作任何其他目的。我们 同意将本鉴证报告作为贵公司年度 ...

Financial Performance - The company achieved operating revenue of CNY 245 million, a year-on-year increase of 43.12%, and a net profit of CNY 29.09 million, up 40.41% year-on-year[5]. - The company’s net profit attributable to shareholders for 2023 was ¥31,681,717.59, a 2.00% increase from ¥31,059,442.05 in 2022[52]. - The company reported a revenue growth of 43.12% during the reporting period, with a net profit growth of 40.41% after deducting non-recurring items[175]. - The company’s operating cash flow net amount was 42.76 million RMB, with a product gross margin of 79.69%[29]. - The company’s gross profit margin for 2023 was 79.69%, slightly down from 80.03% in 2022[52]. - The company experienced a significant increase in other business income, which surged by 8428.29% to ¥48,302.55[91]. - The company’s human interferon α1b injection experienced an average price reduction of 19.38% following the procurement results from the interferon industry[154]. Research and Development - The company has developed a new drug, recombinant human interferon α1b, which is the first genetically engineered drug with independent intellectual property rights in China[6]. - The company is actively advancing four major new drug research projects and has a complete R&D team that has achieved significant results[6]. - The company’s R&D expenditures increased by 44.72% to 121.21 million, driven by clinical trials for new treatments[19]. - The company is conducting a Phase III clinical trial for nebulized human interferon α1b treatment for pediatric RSV pneumonia, which addresses a significant clinical need in treating respiratory infections in children[70]. - The company is conducting a Phase III clinical trial for interferon α1b to treat COVID-19, which is expected to enhance its market share and brand influence significantly[114]. - The company is developing new clinical value products, such as γδT cell therapy, which aligns with its existing product lines and reduces innovation risks[179]. Market Expansion and Sales Strategy - The company added 460 new medical terminals in regions benefiting from exclusive procurement, with sales in Henan and Guangdong increasing by 308.96% and 345.30% year-on-year, respectively[13]. - The company has established a robust sales network that ensures its products reach various healthcare service endpoints nationwide[66]. - The company is actively expanding its marketing network, focusing on city-level hospitals and grassroots medical markets, to enhance its sales strategy and achieve annual sales targets[82]. - The company is focusing on the growing demand for pediatric medications, with policies expected to stimulate the development of this market segment[74]. - The company has successfully expanded its market presence, with sales volume in certain regions increasing by over 300% despite a decrease in profit margins due to competitive pricing[94]. Technological Advancements - The company is implementing an "Industry 4.0" strategy in its new intelligent production and R&D base, utilizing advanced technologies such as big data and artificial intelligence[9]. - The company has established five technology platforms to support the development of various drug formulations, including injection solutions and inhalation agents[6]. - The new intelligent production and R&D base project is designed to achieve an annual production capacity of over 100 million units, including various dosage forms such as powder injections and nebulized inhalation agents[74]. - The company has introduced advanced information systems such as SCADA, DCS, and MES in its new plant to enhance production efficiency and quality, aiming for cost reduction and efficiency improvement[142]. Financial Position and Assets - Cash and cash equivalents decreased by 21.26% to 177.51 million, accounting for 14.37% of total assets[17]. - Accounts receivable increased by 17.09% to 83.60 million, representing 6.77% of total assets[17]. - Construction in progress surged by 138.83% to 639.37 million, now comprising 51.76% of total assets[17]. - Total assets at the end of 2023 reached ¥1,235,173,866.83, a 32.30% increase from ¥933,631,678.93 at the end of 2022[57]. - The company's total equity attributable to shareholders was ¥610,938,566.99, a 6.28% increase from ¥574,814,325.65 in 2022[57]. Government Support and Industry Trends - The biopharmaceutical industry is receiving increased policy support from the government, which is expected to drive high-quality development in the sector[14]. - The government has introduced favorable policies for the pharmaceutical industry, aiming to enhance innovation and competitiveness, which is expected to drive demand for medical products[88]. - The government has increased support for the biopharmaceutical industry, encouraging drug innovation and prioritizing the review and approval of innovative drugs[71]. Corporate Social Responsibility and Recognition - The company was recognized as a 2023 Forbes China ESG Innovative Enterprise at the Forbes China ESG Innovation Enterprise Selection Summit[29]. - The company actively participated in social responsibility initiatives, including rural poverty alleviation and community support activities during the reporting period[132]. - The company has been recognized as "2022 China's Annual Preferred Employer" and "2023 China's Annual Preferred Employer" by Peking University and Zhaopin[140]. - The company has received numerous certifications and awards, including being recognized as a National High-tech Enterprise and a National Intellectual Property Demonstration Enterprise[69]. Risk Management - The company has faced risks related to increased competition in the biopharmaceutical sector, necessitating a focus on differentiation and clinical evidence to support new indications for its products[178]. - The company has not reported any significant changes in major risks during the reporting period[181]. - There are no new risk factors identified during the reporting period[182].

关于北京三元基因药业股份有限公司 控股股东及其他关联方 资金占用情况的专项说明 关于北京三元基因药业股份有限公司 控股股东及其他关联方资金占用情况的专项说明 CAC证专字[2024]0049号 北京三元基因药业股份有限公司全体股东: CAC 证专字[2024]0049 号 中审华会计师事务所（特殊普通合伙） 目 录 项目 页次 一、控股股东及其他关联方资金占用情况的专项说明 1-2 二、北京三元基因药业股份有限公司 2023 年度非经营性资金占 用及其他关联资金往来情况统计表 3 我们审计了北京三元基因药业股份有限公司（以下简称"三元基因"）2023 年 12 月 31 日合并及母公司资产负债表、2023 年度的合并及母公司利润表、现金流量 表、股东权益变动表以及财务报表附注（以下简称"财务报表"），并出具了报告号 为 CAC 证审字[2024]0033 号的无保留意见审计报告。财务报表的编制和公允列报是 三元基因管理层的责任，我们的责任是在按照中国注册会计师审计准则执行审计工 作的基础上对财务报表整体发表审计意见。 根据中国证券监督管理委员会、中华人民共和国公安部、国务院国有资产监督管 理委员会、中国银行保 ...